Literature DB >> 21152980

Importance of hypogonadism and testosterone replacement therapy in current urologic practice: a review.

Wayne J G Hellstrom1, Darius Paduch, Craig F Donatucci.   

Abstract

Evaluation of potential candidates for testosterone replacement therapy (TRT) includes a complete medical history, physical examination, and hormonal screening. The choice of testosterone assay is important in clinical decision making. TRT should, in theory, approximate natural endogenous production of the hormone. There is no apparent association between TRT and the development of prostate cancer. The administration of exogenous testosterone is not a means of reversing the aging process in men with normal testosterone levels, but it may offer considerable benefit for those with hypogonadism.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 21152980     DOI： 10.1007/s11255-010-9879-4

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN： 0301-1623            Impact factor:   2.370


  40 in total

Review 1.  Prostate cancer risk in testosterone-treated men.

Authors:  Jean-Pierre Raynaud
Journal:  J Steroid Biochem Mol Biol       Date:  2006-12       Impact factor: 4.292

2.  Assessing hypogonadism in men--how helpful are current testosterone assays?

Authors:  Julie D Newman; James C G Doery
Journal:  Aust Fam Physician       Date:  2008-08

3.  Direct measurement of serum free testosterone by ultrafiltration followed by liquid chromatography tandem mass spectrometry.

Authors:  Yu Chen; Mehrdad Yazdanpanah; Xiao Yan Wang; Barry R Hoffman; Eleftherios P Diamandis; Pui-Yuen Wong
Journal:  Clin Biochem       Date:  2009-12-21       Impact factor: 3.281

4.  Androgen therapy in women: an Endocrine Society Clinical Practice guideline.

Authors:  Margaret E Wierman; Rosemary Basson; Susan R Davis; Sundeep Khosla; Karen K Miller; William Rosner; Nanette Santoro
Journal:  J Clin Endocrinol Metab       Date:  2006-10-03       Impact factor: 5.958

5.  Reproducibility studies and interlaboratory concordance for androgen assays in female plasma.

Authors:  T R Fears; R G Ziegler; J L Donaldson; R T Falk; R N Hoover; F Z Stanczyk; J B Vaught; M H Gail
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2000-04       Impact factor: 4.254

6.  Free testosterone is an independent predictor of BMD and prevalent fractures in elderly men: MrOS Sweden.

Authors:  Dan Mellström; Olof Johnell; Osten Ljunggren; Anna-Lena Eriksson; Mattias Lorentzon; Hans Mallmin; Anna Holmberg; Inga Redlund-Johnell; Eric Orwoll; Claes Ohlsson
Journal:  J Bone Miner Res       Date:  2006-04-05       Impact factor: 6.741

Review 7.  Vascular smooth muscle and endothelial functions in aging.

Authors:  Oguzhan Yildiz
Journal:  Ann N Y Acad Sci       Date:  2007-04       Impact factor: 5.691

8.  Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions.

Authors:  Anthony V D'Amico; James W Denham; Juanita Crook; Ming-Hui Chen; Samuel Z Goldhaber; David S Lamb; David Joseph; Keen-Hun Tai; Shawn Malone; Charles Ludgate; Allison Steigler; Philip W Kantoff
Journal:  J Clin Oncol       Date:  2007-06-10       Impact factor: 44.544

9.  Prevalence of androgen deficiency in men with erectile dysfunction.

Authors:  Tobias S Köhler; Johnny Kim; Kendall Feia; Josh Bodie; Nick Johnson; Antoine Makhlouf; Manoj Monga
Journal:  Urology       Date:  2008-03-03       Impact factor: 2.649

10.  Investigation, treatment and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA and ASA recommendations.

Authors:  C Wang; E Nieschlag; R Swerdloff; H M Behre; W J Hellstrom; L J Gooren; J M Kaufman; J-J Legros; B Lunenfeld; A Morales; J E Morley; C Schulman; I M Thompson; W Weidner; F C W Wu
Journal:  Eur J Endocrinol       Date:  2008-11       Impact factor: 6.664
View more
  7 in total

1.  Testosterone Therapy in Patients with Treated and Untreated Prostate Cancer: Impact on Oncologic Outcomes.

Authors:  Jesse Ory; Ryan Flannigan; Colin Lundeen; James G Huang; Peter Pommerville; S Larry Goldenberg
Journal:  J Urol       Date:  2016-04-27       Impact factor: 7.450

Review 2.  Update on Testosterone Replacement Therapy in Hypogonadal Men.

Authors:  Kevin Matthew Yen Bing Leung; Khalid Alrabeeah; Serge Carrier
Journal:  Curr Urol Rep       Date:  2015-08       Impact factor: 3.092

3.  Changes in the levels of testosterone profile over time in relation to clinical parameters in a cohort of patients with prostate cancer managed by active surveillance.

Authors:  Ahmed S Zakaria; Alice Dragomir; Wassim Kassouf; Simon Tanguay; Armen Aprikian
Journal:  World J Urol       Date:  2018-03-20       Impact factor: 4.226

4.  Testosterone replacement therapy in patients with prostate cancer after radical prostatectomy.

Authors:  Alexander W Pastuszak; Amy M Pearlman; Win Shun Lai; Guilherme Godoy; Kumaran Sathyamoorthy; Joceline S Liu; Brian J Miles; Larry I Lipshultz; Mohit Khera
Journal:  J Urol       Date:  2013-02-08       Impact factor: 7.450

Review 5.  Testosterone deficiency in adults and corresponding treatment patterns across the globe.

Authors:  James Anaissie; Kent J DeLay; William Wang; Georgios Hatzichristodoulou; Wayne J Hellstrom
Journal:  Transl Androl Urol       Date:  2017-04

Review 6.  Quality of Life and Sexual Health in the Aging of PCa Survivors.

Authors:  Mauro Gacci; Elisabetta Baldi; Lara Tamburrino; Beatrice Detti; Lorenzo Livi; Cosimo De Nunzio; Andrea Tubaro; Stavros Gravas; Marco Carini; Sergio Serni
Journal:  Int J Endocrinol       Date:  2014-03-17       Impact factor: 3.257

7.  Assessment of an ethanolic seed extract of Picralima nitida ([Stapf] Th. and H. Durand) on reproductive hormones and its safety for use.

Authors:  Lydia Francisca Otoo; George Asumeng Koffuor; Charles Ansah; Kwesi Boadu Mensah; Charles Benneh; Inemesit Okon Ben
Journal:  J Intercult Ethnopharmacol       Date:  2015-11-02
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.